Recombinant Mycobacterium bovis BCG as an HIV vaccine vector
- PMID: 20353397
- PMCID: PMC3188323
- DOI: 10.2174/157016210791208686
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector
Abstract
HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine. Numerous features make BCG an attractive vehicle to deliver HIV antigens. It has a good safety profile, elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable, a necessary consideration for developing countries. In this review we discuss the numerous factors that influence generation of a genetically stable recombinant BCG vaccine for HIV.
References
-
- Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I. Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand. 1995;84:229–236. - PubMed
-
- Champlin R, Hunter RL. Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J Immunol. 1975;114(1 Pt 1):76–80. - PubMed
-
- Gheorghiu M, Lagrange PH, Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand. 1988;16(1):15–26. - PubMed
-
- Roche PW, Triccas JA, Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol. 1995;3(10):397–401. - PubMed
-
- Fennelly GJ, Flynn JL, ter MV, Liebert UG, Bloom BR. Recombinant bacille Calmette-Guerin priming against measles. J Infect Dis. 1995;172(3):698–705. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources